Home Cart Sign in  
Chemical Structure| 106566-58-9 Chemical Structure| 106566-58-9

Structure of Ossirene
CAS No.: 106566-58-9

Chemical Structure| 106566-58-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AS101 is a potent Caspase-1 inhibitor which can inhibit IL-10 synthesis and potentiates IL-1α, IL-2 and TNF-α release through Caspase, performing as an immunomodulator.

Synonyms: AS101

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ossirene

CAS No. :106566-58-9
Formula : C2H8Cl3NO2Te
M.W : 312.05
SMILES Code : [Cl-][Te+4]1([Cl-])([O-]CC[O-]1)[Cl-].[NH4+]
Synonyms :
AS101
MDL No. :MFCD01682758

Safety of Ossirene

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ossirene

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MLN cells 0.1, 0.5, 1 µg/ml 2 h AS101 significantly reduced the adhesion of MLN cells to MAdCAM-1 PMC4059162
Wehi-3B mouse myeloid monocytic leukemia cells 1 μg/ml 24 h AS101 completely abrogated PD-L1 expression PMC11380454
Human AML cells 1 μg/ml 24 h AS101 completely abrogated PD-L1 expression PMC11380454
B16/F10 melanoma cells 1 μg/ml 24 h AS101 completely abrogated PD-L1 expression PMC11380454
R161H-Foxp3-GFP LN cells 0.1, 0.3, 1 μg/ml 96 h AS101 promotes Treg differentiation independently of TGF-β PMC6513711
D122 mouse adenocarcinoma alveolar basal epithelial cells 1 μg/ml 24 h AS101 completely abrogated PD-L1 expression PMC11380454
R161H LN cells 0.1, 0.3, 1 μg/ml 72 h AS101 inhibits Th1 and Th17 polarization, reducing IFN-γ and IL-17A expressing cells PMC6513711
Glomerular macrophages 1 µg/ml 24 h AS101 significantly inhibited IL-1β secretion and caspase-1 activity in macrophages, indicating that AS101 inhibits caspase-1 activation by suppressing VLA-4 activity. PMC5339302

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice B16/F10 melanoma model Intraperitoneal injection 1 mg/kg Every other day, until tumor volume reached 2000 mm³ AS101 significantly reduced tumor volume, decreased PD-L1 expression on tumor cells, and increased CD8+ T-cell infiltration into the tumor PMC11380454
Mice Experimental autoimmune uveitis (EAU) Intraperitoneal injection 27 μg/mouse Daily for 14 consecutive days AS101 increases Treg cells, reduces Th1 and Th17 effector cells, and attenuates EAU PMC6513711
C57BL/6 mice DSS-induced colitis model Intraperitoneal or oral 10 µg/mouse (intraperitoneal) or 100 µg/mouse (oral) Daily administration for 7 days AS101 significantly alleviated clinical symptoms of DSS-induced colitis, reduced inflammatory cell infiltration, and protected colonic epithelial barrier function PMC4059162
Rats Crescentic glomerulonephritis model Intraperitoneal injection 100 µg/rat Daily injections for 21 days AS101 significantly improved renal function, reduced crescent formation, and inhibited inflammatory mediators and macrophage infiltration in the crescentic glomerulonephritis model. PMC5339302

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00418249 Alopecia PHASE2 UNKNOWN - Tel Aviv, Israel
NCT01010373 Acute Myeloid Leukemia|Myelody... More >>splastic Syndrome Less << PHASE2 SUSPENDED 2025-01-16 Sheba Medical Center, Tel Hash... More >>omer, Israel Less <<
NCT00926354 Chemotherapy Induced Thrombocy... More >>topenia Less << PHASE2 TERMINATED 2025-08-10 Meir Medical Center, Kfar Saba... More >>, Israel Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.20mL

0.64mL

0.32mL

16.02mL

3.20mL

1.60mL

32.05mL

6.41mL

3.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories